The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.
Vishnu KumarasamyJianxin WangCostakis FrangouYin WanAndrew DynkaHanna R RosenheckPrasenjit DeyEthan V AbelErik S KnudsenAgnieszka K WitkiewiczPublished in: Cancer research (2024)
Pharmacologic inhibition of KRAS elicits varied responses in pancreatic cancer 2D cell lines, 3D organoid cultures, and xenografts, underscoring the importance of mechanotransduction and the tumor microenvironment in regulating therapeutic responses.
Keyphrases